Skip to content

Alnylam eyed after Ionis Phase 3 data

May 15, 2017

Alnylam Pharma (NASDAQ: ALNY) was in focus Monday morning after Ionis Pharma (NASDAQ: IONS) reported that the Phase 3 NEURO-TTR study of inotersen in patients with familial amyloid polyneuropathy (FAP) met both primary endpoints.

The Street columnist Adam Feuerstein said on twitter the data looks bad, which is good for Alnylam.

TTR ph3 safety looks bad, good for . (I’m on a plane)

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: